ALGS · XBRL financial data

Aligos Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ALGS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	0	0	0	6,191	3,611	2,186
Research and development	79,890	104,153	85,077	73,040	70,269	69,453
General and administrative	17,944	28,527	26,410	30,616	22,830	20,718
Total operating expenses	97,834	132,680	111,487	103,656	93,099	90,171
Other operating income (expense)	(10,548)	132	1,640	1,243	4,406	3,922
Operating income (loss)	(97,834)	(128,321)	(97,580)	(88,127)	(89,154)	(87,985)
Income tax expense (benefit)	161	143	106	795	331	314
Net income (loss)	(108,543)	(128,332)	(96,046)	(87,679)	(131,211)	(24,193)
Earnings per share, basic‡ USD per share	—	—	(56.25)	(34.00)	(20.94)	(2.45)
Earnings per share, diluted‡ USD per share	—	—	(56.25)	(34.00)	(20.94)	(2.45)
Weighted average shares, basic‡ thousands of shares	—	—	1,708	2,570	6,265	9,885
Weighted average shares, diluted‡ thousands of shares	—	—	1,708	2,570	6,265	9,885

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (August 2024); filings made before it reported them unadjusted.

Fiscal years (ALGS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	220,383	186,816	81,347	135,704	36,997	18,303
Short-term investments	23,130	3,918	44,480	—	19,942	59,541
Total current assets	250,017	204,424	133,545	141,084	62,141	82,862
Property and equipment, net	8,007	6,180	4,816	3,259	2,362	1,867
Right-of-use asset	6,901	8,789	7,698	6,559	4,964	3,089
Total assets	265,302	235,369	146,693	151,527	70,094	88,533
Accounts payable	3,313	3,015	4,737	2,517	2,571	3,982
Accrued liabilities	16,564	25,394	16,039	16,842	15,557	13,526
Total current liabilities	30,274	38,957	33,129	23,906	21,737	21,233
Lease liability, non-current	10,371	11,287	9,201	7,668	4,795	1,525
Total liabilities	45,263	50,638	42,793	59,447	99,067	34,988
Accumulated deficit	(174,740)	(303,072)	(399,118)	(486,797)	(618,008)	(642,201)
Total stockholders' equity	220,039	184,731	103,900	92,080	(28,973)	53,545
Total liabilities and equity	265,302	235,369	146,693	151,527	70,094	88,533
Common shares outstanding (cover page)‡ thousands of shares	1,526	1,708	1,717	3,004	3,864	6,178

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (August 2024); filings made before it reported them unadjusted.

Fiscal years (ALGS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(108,543)	(128,332)	(96,046)	(87,679)	(131,211)	(24,193)
Stock-based compensation	2,975	13,457	14,693	12,652	8,452	5,044
Net cash from operating activities	(74,263)	(115,662)	(79,389)	(78,997)	(80,743)	(82,503)
Purchases of property and equipment	2,064	892	943	19	130	—
Net cash from investing activities	32,755	3,022	(26,293)	44,981	(18,279)	(37,826)
Proceeds from issuing common stock	—	—	—	23	—	—
Net cash from financing activities	192,348	78,677	164	88,328	355	101,635

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aligos Therapeutics	30,381	0	(24,950)*	6.2M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
CEL-SCI	6,527	not reported	(4,031)*	17.6M	1.6 quarters	Q3 FY26 10-QJun 30, 2026
Relmada Therapeutics	11,334	not reported	(9,606)*	106.7M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
Fibrogen	50,644	(1,474)	(3,991)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026
Armata Pharmaceuticals	23,952	not reported	(8,666)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Imunon	6,864	not reported	(3,025)*	5.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Lunai Bioworks	1,714	31*	(1,841)*	5.0M	0.9 quarters	Q4 FY26 10-KJun 30, 2026
Dare Bioscience	12,618	188	(6,775)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
IGC Pharma	331	265	(1,350)*	103.4M	0.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.